Epidemiology and molecular monitoring of HIV...

In the News

Muhas don is new IHI board member

Prof. Kaaya. Ifakara Health Institute (IHI) Board of Governors (BOG) has appointed Prof. Sylvia Kaaya member of the IHI Board of Trustees (BOT) effective Wednesday January 10, 2018. The appointment …

Marcel steps down from IHI boards

Prof. Marcel Tanner has stepped down as Ifakara Health Institute (IHI) member of the Board of Trustees (BOT) and Board of Governors (BOG) effective Wednesday January 10, 2018. The Former …

Recent Projects

Understanding and enhancing approaches to quality improvement in small and medium sized private facilities in sub-Saharan Africa

This is an evaluation study that IHI is conducting in collaboration with London school of hygiene and tropical medicine. The research takes place in the context of an innovative intervention …

Vaccine Delivery Costing Study

As countries drive towards achieving high and equitable coverage of life-saving vaccines, the availability of sustainable, equitable, and predictable financing for vaccine delivery is essential. Over the last two decades, …

Epidemiology and molecular monitoring of HIV drug resistance in Tanzania.

The prognosis of HIV/AIDS has dramatically changed after the introduction of potent anti-retroviral therapy in the mid 90’s with a more than 80 percent decrease of mortality and morbidity where anti-retroviral therapy (ART) is available. Most of the data about the out-come of patients living with HIV/AIDS (PLWHAs) under ART are generated by cohort studies in developed countries. Since 2004 the Tanzanian National HIV/AIDS Control and Treatment Plan (NACP) provides ART in Tanzania. The Chronic Diseases Clinic in Ifakara (CDCCI) at the St. Francis Designated District Hospital (SFDDH) is on of the first rural clinics accredited by and implementing the aims of NACP since May 2005. Until mid September 2008 3,003 PLWHAs were included in the NACP and 1,677 started with ART at CDCI. To our knowledge, studies on the outcome of PLWHAs cared for in rural Sub-Saharan Africa are scarce.

The Kilombero-Ulanga-Anti-Retroviral-Cohort (KUILARCO) intents to generate data on clinical out-come, behavior changes, social conditions, and adherence to ART of PLWHAs attending CDCI and thereby to fill the gap of our knowledge about the impact of the availability of ART in rural Tanzania. Based on the successful start of the cohort at CDCI of SFDHH in Ifakara, the intention is to extend the study to other sites of the Ifakara Health Institute (IHI) namely the sites in Bagamoyo, Dar es Salaam and Rufiji and to share the gained knowledge to the benefit of a more extended population of PLWHAs of the United Republic of Tanzania.

The goal of this project is to collect data on treatment outcomes of PLWHAs undert ART and adherence of ART treated at CDCI at SFDDH district level-according the NACP guidelines. In a first phase these parameters are analyzed at CDCI of SFDDH. In a second phase, the gained experience of CDCI- as one of the first and largest rural competence centres – will be made available and implemented at health care facilities in Bagamoyo, Dar es Salaam, Rufiji and other settings.

Lead Scientists:

Maja Weisser


Swiss Tropical and Public Health Institute
Ministry of Health Community Development, Gender, Elderly and Children (MoHCDGEC) Tanzania


Ifakara Health Institute
Swiss National Science Foundation

Projects Location

© Ifakara Health Institute (IHI), 2016